Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N A Harris

Showing results (171-180 of 177) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 177 results.
Intensive Care Medicine|March 13, 2024
Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsisMing G Chai, Quyen Tu, Menino O Cotta, et al.
Infectious Diseases (London, England)|July 1, 2023
Higher rates of cefiderocol resistance among NDM producing <i>Klebsiella</i> bloodstream isolates applying EUCAST over CLSI breakpointsBurcu Isler, Cansel Vatansever, Berna Özer, et al.
International Journal of Antimicrobial Agents|August 8, 2017
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT studyPatrick N A Harris, M Diletta Pezzani, Belén Gutiérrez-Gutiérrez, et al.
The Lancet. Infectious Diseases|October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trialDavid L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
JAMA|September 13, 2018
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical TrialPatrick N A Harris, Paul A Tambyah, David C Lye, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 27, 2020
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyA Henderson, D L Paterson, M D Chatfield, et al.
The Journal of Antimicrobial Chemotherapy|May 13, 2026
Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infectionsAbdullah T Aslan, Yukiko Ezure, Elif Seren Tanriverdi, et al.
Pageof 18

Showing results (171-180 of 177) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 177 results.
Intensive Care Medicine|March 13, 2024
Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsisMing G Chai, Quyen Tu, Menino O Cotta, et al.
Infectious Diseases (London, England)|July 1, 2023
Higher rates of cefiderocol resistance among NDM producing <i>Klebsiella</i> bloodstream isolates applying EUCAST over CLSI breakpointsBurcu Isler, Cansel Vatansever, Berna Özer, et al.
International Journal of Antimicrobial Agents|August 8, 2017
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT studyPatrick N A Harris, M Diletta Pezzani, Belén Gutiérrez-Gutiérrez, et al.
The Lancet. Infectious Diseases|October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trialDavid L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
JAMA|September 13, 2018
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical TrialPatrick N A Harris, Paul A Tambyah, David C Lye, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 27, 2020
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyA Henderson, D L Paterson, M D Chatfield, et al.
The Journal of Antimicrobial Chemotherapy|May 13, 2026
Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infectionsAbdullah T Aslan, Yukiko Ezure, Elif Seren Tanriverdi, et al.
Pageof 18